Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
Genmab's Phase 3 LiGeR-HN1 trial met both co-primary endpoints at the first interim analysis, with petosemtamab plus pembrolizumab cutting the risk of death by 50% (OS HR 0.50, p<0.0001) in first-line PD-L1+ recurrent/metastatic head and neck cancer. Objective response rate also improved significantly (odds ratio 3.17, p<0.0001), regardless of HPV status, and no new safety signals were identified.
Key figures
- Drug Name
- petosemtamab (GEN1158)
- Phase Of Trial
- Phase 3
- Trial
- LiGeR-HN1
- Trial nct
- NCT06525220
- Os p value
- p<0.0001
- Orr p value
- p<0.0001
- Orr odds ratio
- 3.17
- Os hazard ratio
- 0.5
- Orr odds ratio ci
- 95% CI, 2.06, 4.89
- Os hazard ratio ci
- 95% CI, 0.37, 0.67
- Risk of death reduction
- 50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.